US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

18.91

+0.37002.00%

Post-market: 18.910.00000.00%16:04 EDT

Volume:335.52K

Turnover:6.29M

Market Cap:545.98M

PE:-102.51

High:19.06

Open:18.51

Low:17.89

Close:18.54

Loading ...

Overview Company News Filings

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

Castle Biosciences Says TissueCypher Test Approved by New York Health Department

MT Newswires Live

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

BRIEF-Castle Biosciences's Tissuecypher Barrett's Esophagus Test Receives New York State Department Of Health Approval

Castle Biosciences gets NYSDOH approval for TissueCypher BE test

Castle Biosciences Inc: New York State Department of Health Approval of Its Tissuecypher Barrett's Esophagus Test

THOMSON REUTERS

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Neumora Stock Hits Record Low on Depression Drug Study Failure

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Castle Biosciences Price Target Maintained With a $41.00/Share by Stephens & Co.

Stephens lays out 21 Best Ideas for 2025

JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723

BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer

Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek

AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC

Analysts’ Top Healthcare Picks: Lifecore Biomedical (LFCR), Castle Biosciences (CSTL)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSTL/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","market":"US","secType":"STK","nameCN":"Castle Biosciences, Inc.","latestPrice":18.91,"timestamp":1750276800000,"preClose":18.54,"halted":0,"volume":335521,"hourTrading":{"tag":"盘后","latestPrice":18.91,"preClose":18.91,"latestTime":"16:04 EDT","volume":11026,"amount":208501.66,"timestamp":1750277052166},"delay":0,"floatShares":26464372,"shares":28872315,"eps":-0.184478,"marketStatus":"Closed Juneteenth National Independence Day","change":0.37,"latestTime":"06-18 16:00:00 EDT","open":18.51,"high":19.0625,"low":17.8862,"amount":6294771.903825,"amplitude":0.063447,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.184478,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750406400000},"marketStatusCode":7,"adr":0,"listingDate":1564027200000,"exchange":"NASDAQ","adjPreClose":18.54,"preHourTrading":{"tag":"盘前","latestPrice":18.54,"preClose":18.54,"latestTime":"08:00 EDT","volume":1,"amount":18.54,"timestamp":1750248000927},"postHourTrading":{"tag":"盘后","latestPrice":18.91,"preClose":18.91,"latestTime":"16:04 EDT","volume":11026,"amount":208501.66,"timestamp":1750277052166},"volumeRatio":0.6806293447873232,"impliedVol":0.3351,"impliedVolPercentile":0.024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","floatShares":26464372,"roa":"-1.79%","roe":"-1.20%","lyrEps":0.656862,"volumeRatio":0.6806293447873232,"shares":28872315,"dividePrice":0,"high":19.0625,"amplitude":0.063447,"preClose":18.54,"low":17.8862,"week52Low":15.45,"pbRate":"1.24","psRate":"1.57","week52High":35.84,"institutionHeld":0,"latestPrice":18.91,"eps":-0.184478,"divideRate":0,"volume":335521,"delay":0,"ttmEps":-0.184478,"open":18.51,"prevYearClose":26.65,"prevWeekClose":18.75,"prevMonthClose":15.97,"prevQuarterClose":20.02,"fiveDayClose":18.44,"twentyDayClose":16.5,"sixtyDayClose":20.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSTL\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2501662462","title":"Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2501662462","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501662462?lang=en_us&edition=fundamental","pubTime":"2025-01-07 00:54","pubTimestamp":1736182440,"startTime":"0","endTime":"0","summary":"Vanda Pharmaceuticals Inc. VNDA generates revenues from the sale of its three commercial products, Fanapt, Hetlioz and Ponvory.Fanapt is approved in the United States for two indications, schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. Hetlioz is approved to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome.Ponvory is an oral treatment approved to treat relapsing forms of multiple sclerosis. VNDA acquired the United States and Canada rights to Ponvory from Actelion Pharmaceuticals Limited, a subsidiary of Johnson & Johnson JNJ, in December 2023.JNJ gained approval for Ponvory as an oral treatment for adults with relapsing forms of multiple sclerosis in 2021.In the past year, shares of Vanda have gained 13.9% against the industry’s decline of 16%.In the past 60 days, estimates for Puma Biotechnology’s 2025 earnings per share have increased from 42 cents to 54 cents. In the past year, shares o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/good-idea-invest-vanda-pharmaceuticals-165400674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BSNM7G36.USD","LU0234572021.USD","IE0002270589.USD","IE00BVYPNV92.GBP","IE00B1BXHZ80.USD","ASO","LU0466842654.USD","CSTL","IE000M9KFDE8.USD","LU0882574055.USD","LU0122379950.USD","LU1057294990.SGD","LU1074936037.SGD","LU1732799900.SGD","LU1221951046.USD","BK4568","LU1929549753.HKD","LU2089984988.USD","VNDA","LU1066051811.HKD","LU1674673428.USD","BK4592","LU0889566641.SGD","BK4007","LU1506573853.SGD","IE00BFTCPJ56.SGD","PBYI","IE0009355771.USD","LU1196500208.SGD","SG9999002224.SGD","LU1261432733.SGD","LU1914381329.SGD","BK4533","LU1718418525.SGD","LU0792757196.USD","LU1032466523.USD","LU0203345920.USD","LU2468319806.SGD","LU0320765646.SGD","LU0640476718.USD","BK4581","LU0345769631.USD","LU1059921491.USD","LU0058720904.USD","JNJ","IE00BJJMRZ35.SGD","IE00B3PB1722.GBP","SG9999001440.SGD","LU1430594728.SGD","LU0795875086.SGD"],"gpt_icon":0},{"id":"2501810230","title":"Castle Biosciences Says TissueCypher Test Approved by New York Health Department","url":"https://stock-news.laohu8.com/highlight/detail?id=2501810230","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501810230?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:23","pubTimestamp":1736173392,"startTime":"0","endTime":"0","summary":"Castle Biosciences  said Monday it has received approval from the New York State Department of Health for its TissueCypher test, a tool designed to assess the risk of progression from Barrett's esophagus to esophageal cancer.The company said the approval expands its New York Clinical Laboratory Permit to include this test, along with others in its dermatology, gastroenterology, and ophthalmology portfolios.Shares of the company were up 4.2% in recent Monday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2501025191","title":"KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2501025191","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501025191?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:59","pubTimestamp":1736171940,"startTime":"0","endTime":"0","summary":"Shares of Kodiak Sciences KOD have skyrocketed 270.7% in the past six months fueled by updates from the developmental program of its lead investigational candidate, tarcocimab. It is a novel anti-VEGF antibody biopolymer conjugate, which is being evaluated for treating retinal vascular diseases.In late 2023, Kodiak rebooted the development program of tarcocimab following positive phase III results from the GLOW1 study, which evaluated the treatment in patients with moderately severe to severe non-proliferative diabetic retinopathy. Leveraging the GLOW1 study's success, Kodiak initiated the GLOW2 study in late 2023 to further investigate tarcocimab for diabetic retinopathy  and began dosing patients in May 2024, with enrollment expected to be completed soon. The success of the GLOW2 study is expected to serve as the basis for a single biologics license application submission for tarcocimab, seeking its approval for DR.The revival of tarcocimab in Kodiak's pipeline, after a major setback","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kod-stock-rallies-271-6-135900100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KOD","CSTL","BK4505","CTMX","VNDA","BK4196","BK4139"],"gpt_icon":0},{"id":"2501331862","title":"BRIEF-Castle Biosciences's Tissuecypher Barrett's Esophagus Test Receives New York State Department Of Health Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2501331862","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501331862?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:16","pubTimestamp":1736165806,"startTime":"0","endTime":"0","summary":"BRIEF-Castle Biosciences's Tissuecypher Barrett's Esophagus Test Receives New York State Department Of Health ApprovalJan 6 (Reuters) - Castle Biosciences Inc CSTL.O:CASTLE BIOSCIENCES INC:  NEW YORK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3NZ0M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2501223311","title":"Castle Biosciences gets NYSDOH approval for TissueCypher BE test","url":"https://stock-news.laohu8.com/highlight/detail?id=2501223311","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501223311?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:10","pubTimestamp":1736165456,"startTime":"0","endTime":"0","summary":"Castle Biosciences (CSTL) announced that it has received assay approval from the New York State Department of Health NYSDOH for its TissueCypher Ba...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/castle-biosciences-gets-nysdoh-approval-for-tissuecypher-be-test?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/castle-biosciences-gets-nysdoh-approval-for-tissuecypher-be-test?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0444971666.USD","BE","BK4541","LU1642822529.SGD","LU0444973449.USD","LU0476273544.USD","LU2249611893.SGD","LU2506951792.HKD","LU0823414551.USD","BK4196","LU2294711713.HKD","LU0957808578.USD","LU2357125470.USD","LU0823414478.USD","BK4182","LU1815336760.USD","BK4588","BK4585","CSTL"],"gpt_icon":0},{"id":"2501780238","title":"Castle Biosciences Inc:  New York State Department of Health Approval of Its Tissuecypher Barrett's Esophagus Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2501780238","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501780238?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:04","pubTimestamp":1736165062,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3NZ0M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2500263831","title":"Here's Why Arcutis Stock More Than Doubled in Market Value in One Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2500263831","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500263831?lang=en_us&edition=fundamental","pubTime":"2025-01-04 02:28","pubTimestamp":1735928880,"startTime":"0","endTime":"0","summary":"Shares of small biotech Arcutis Biotherapeutics ARQT have surged nearly three times in market value in the past year.The upside has been primarily driven by the positive regulatory updates regarding the company’s efforts to expand the label of its only marketed product, Zoryve.This drug is currently approved for use in different formulations – as foam and cream – across different indications.In the past year, Arcutis’ stock has skyrocketed over 272% against the industry’s 14.1% fall.In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past year, Spero’s shares have lost 26.5%.SPRO’s earnings beat estimates in two of the trailing four quarters and missed the m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-arcutis-stock-more-182800155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","ARQT","BK4196","BK4139","CTMX","SPRO"],"gpt_icon":0},{"id":"2500141989","title":"MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2500141989","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500141989?lang=en_us&edition=fundamental","pubTime":"2025-01-03 23:56","pubTimestamp":1735919760,"startTime":"0","endTime":"0","summary":"Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease  in children aged two months and older, including adolescents and teenagers. The drug has a novel mechanism of action and will be marketed under the brand name Ryoncil in the United States.The approval gave Mesoblast its first approved product in its portfolio. Sales of the drug are expected to provide the company with a steady source of income. The company is currently gearing up to launch the product in the U.S. market.SR-aGVHD is a devastating condition that has an extremely poor prognosis. Each year in the United States, around 10,000 patients, including 1,500 children, undergo allogeneic bone marrow transplants. About 50% develop aGvHD, and nearly half of these cases are steroid-resistant.In the past six months, shares of Mesoblast have skyrocketed 202.9% against the industry’s 4.8% decline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meso-stock-surges-80-month-155600622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4139","CTMX","MSB.AU","SPRO","BK4196","MESO"],"gpt_icon":0},{"id":"2500981141","title":"CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2500981141","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500981141?lang=en_us&edition=fundamental","pubTime":"2025-01-03 23:23","pubTimestamp":1735917780,"startTime":"0","endTime":"0","summary":"Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application  to the FDA seeking full approval for deramiocel to treat patients diagnosed with Duchenne muscular dystrophy  cardiomyopathy. CAPR’s lead product candidate and only clinical pipeline asset, deramiocel, is an investigational, allogeneic cardiac-derived cell therapy. A final decision of the FDA is anticipated in the second half of 2024.Capricor initiated its rolling submission process for the deramiocel BLA in October 2024, based on a successful pre-BLA meeting with the FDA. The completion of the submission process has also triggered a $10 million milestone payment from its distribution partner, Nippon Shinyaku, under the terms of the companies’ U.S. Commercialization and Distribution Agreement. The impending influx of cash is set to strengthen CAPR’s cash position.In the past three months, shares of Capricor have plunged 30.9% compared with the indu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/capr-stock-completion-rolling-submission-152300104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CAPR","BK4196","SPRO","CTMX","CSTL"],"gpt_icon":0},{"id":"2500145917","title":"Neumora Stock Hits Record Low on Depression Drug Study Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2500145917","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500145917?lang=en_us&edition=fundamental","pubTime":"2025-01-03 22:14","pubTimestamp":1735913640,"startTime":"0","endTime":"0","summary":"The phase III KOASTAL-1 study evaluated the efficacy and safety of navacaprant against placebo in adults with moderate-to-severe MDD over a six-week treatment period. The study failed to achieve its primary endpoint – treatment with the drug failed to demonstrate a significant improvement over placebo in alleviating depression symptoms, as measured by the Montgomery-Asberg Depression Rating Scale .The study also failed to show statistically significant improvement in the reduction of anhedonia , as assessed by the Snaith-Hamilton Pleasure Scale .The KOASTAL-1 study is one of the three late-stage studies in the KOASTAL program evaluating navacaprant in the MDD indication. Despite the study's failure, Neumora intends to continue the other two studies. In the meantime, management continues to further analyze the study results, as management claimed that the drug showed an efficacy signal in female patients.Following the news, shares of Neumora hit an all-time low of $1.83. The latest anno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neumora-stock-hits-record-low-141400263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVC","BK4196","BK4007","BK4139","CSTL","CTMX","NMRA","SPRO"],"gpt_icon":0},{"id":"2500902522","title":"PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2500902522","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500902522?lang=en_us&edition=fundamental","pubTime":"2025-01-03 02:28","pubTimestamp":1735842480,"startTime":"0","endTime":"0","summary":"Shares of Precigen PGEN have soared nearly 43% in the past week after the company provided an encouraging regulatory update for its lead pipeline program.Last week, Precigen announced that it has completed a rolling submission for a biologic license application  seeking the FDA’s accelerated approval for PRGN-2012, an experimental gene therapy to treat adults with recurrent respiratory papillomatosis .A rare disease, RRP causes benign tumors  to grow in the respiratory tract, most commonly in the larynx . It is caused by two types of human papilloma virus  – HPV 6 and HPV 11.The BLA is supported by data from a pivotal phase I/II study that evaluated PRGN-2012 for the treatment of adult patients with RRP. Data from the study showed that more than 50% of patients achieved a complete response . Also, more than 85% of patients experienced a reduction in surgical interventions in the year after receiving PRGN-2012 compared to the year before receiving the therapy.Precigen currently carries ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pgen-stock-surges-more-40-182800609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PGEN","CTMX","CSTL","BK4583","BK4196","BK4568","INO","BK4139"],"gpt_icon":0},{"id":"2500974072","title":"MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN","url":"https://stock-news.laohu8.com/highlight/detail?id=2500974072","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500974072?lang=en_us&edition=fundamental","pubTime":"2025-01-02 23:02","pubTimestamp":1735830120,"startTime":"0","endTime":"0","summary":"Shares of Monopar Therapeutics MNPR, a clinical-stage biotech, skyrocketed 383.5% in the past three months fueled by a licensing agreement with AstraZeneca AZN, which granted MNPR an exclusive worldwide license to ALXN-1840 . ALXN-1840 is an investigational once-daily, oral medicine, which is being developed for treating Wilson disease, a rare and progressive genetic disease.AstraZeneca had earlier announced that a pivotal phase III study evaluating the candidate for the above indication had met its primary endpoint. Although AZN terminated the ALXN-1840 program in 2023, Monopar took up the candidate upon the request of the Wilson Disease Association. AstraZeneca’s termination of the ALXN-1840 program was based on the review of results from phase II mechanistic studies and discussions with regulatory authorities.In the past six months, shares of Monopar have rallied 525.5% against the industry’s 4.8% decline.Some other top-ranked stocks from the sector areCastle BiosciencesCSTL andSper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mnpr-stock-skyrockets-384-3-150200991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4568","BK4588","LU2456880835.USD","MNPR","AZN","LU0320765992.SGD","LU1829250122.USD","LU2417539215.USD","LU2462157665.USD","SPRO","LU0889565916.HKD","BK4139","BK4585","BK4196","LU0109394709.USD","LU2236285917.USD","BK4007"],"gpt_icon":1},{"id":"2500007971","title":"VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2500007971","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500007971?lang=en_us&edition=fundamental","pubTime":"2025-01-02 22:56","pubTimestamp":1735829760,"startTime":"0","endTime":"0","summary":"Both avutometinib and defactinib have been in-licensed by Verastem from other pharmaceutical companies. Avutometinib is an RAF/MEK clamp, while defactinib is a best-in-class selective FAK inhibitor.In the past three months, shares of Verastem have surged 86.6% against the industry’s 9.5% decline.More on the FDA Acceptance of Avutometinib NDA for LGSOC. At present, there are no FDA-approved treatments specifically for LGSOC, a rare and distinct type of ovarian cancer with unique biology and treatment responses compared to high-grade serous ovarian cancer, representing a huge unmet medical need. Per Verastem, an estimated 6,000-8,000 women in theUnited Statesand 80,000 worldwide suffer from this disease. The standard of care treatment includes hormone therapy and chemotherapy.Currently, the company is enrolling patients with recurrent LGSOC regardless of KRAS mutation status in the global phase III RAMP 301 study, which is expected to serve as a confirmatory study for the initial indica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vstm-nda-ovarian-cancer-combo-145600394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","VSTM","CTMX","BK4139","SPRO","BK4196"],"gpt_icon":0},{"id":"2500925422","title":"Castle Biosciences Price Target Maintained With a $41.00/Share by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2500925422","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500925422?lang=en_us&edition=fundamental","pubTime":"2025-01-02 21:10","pubTimestamp":1735823400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CSTL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2025 08:10 ET (13:10 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSTL"],"gpt_icon":0},{"id":"2500940013","title":"Stephens lays out 21 Best Ideas for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2500940013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500940013?lang=en_us&edition=fundamental","pubTime":"2025-01-02 20:06","pubTimestamp":1735819560,"startTime":"0","endTime":"0","summary":"Stephens analysts presented the firm’s 2025 Best Ideas list, which includes Valley National (VLY), CoStar Group (CSGP), Castle Biosciences (CSTL), ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/stephens-lays-out-21-best-ideas-for-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/stephens-lays-out-21-best-ideas-for-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4123","LU0708995401.HKD","BK4196","BK4079","LU0109391861.USD","IE0009356076.USD","LU2210149790.SGD","CSGP","LU2095319765.USD","BK4211","BK4585","VLY","BK4588","LU1267930730.SGD","LU0672654240.SGD","LU0320765059.SGD","BK4548","LU2210150020.SGD","LU0390134368.USD","CSTL","IE0004445239.USD"],"gpt_icon":0},{"id":"2494385582","title":"JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723","url":"https://stock-news.laohu8.com/highlight/detail?id=2494385582","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494385582?lang=en_us&edition=fundamental","pubTime":"2024-12-27 20:17","pubTimestamp":1735301820,"startTime":"0","endTime":"0","summary":"How the Licensing Deal for the AD Program Benefits JNJ. The licensing deal with Kaken reinforces Johnson & Johnson’s dedication to targeting disease-specific pathways across diverse patient populations, leveraging innovative mechanisms and approaches to revolutionize the treatment of AD and other autoimmune and allergic conditions.Per JNJ, most AD patients fail to achieve remission with currently available treatments, representing a huge unmet medical need. The company believes that the STAT6 program stands out as a promising research area, offering the potential for a safe and effective novel oral therapy for those suffering from AD and other autoimmune diseases.In the past three months, shares of JNJ have lost 10.2% compared with the industry’s 13.8% decline.Some better-ranked stocks from the sector areCastle BiosciencesCSTL,CytomX TherapeuticsCTMX andSpero TherapeuticsSPRO, each sporting a Zacks Rank #1  at present. You can seethe complete list of today’s Zacks #1 Rank stocks here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jnj-inks-licensing-deal-kaken-121700393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1221951046.USD","LU1674673691.USD","LU1244550494.USD","LU1066051811.HKD","LU1032466523.USD","SG9999002224.SGD","LU0234570918.USD","LU0289739699.SGD","LU0912757837.SGD","BK4532","IE00B3PB1722.GBP","LU1894683348.USD","LU1732799900.SGD","LU1221951129.SGD","LU0203347892.USD","IE00BGHQF631.EUR","CSTL","IE00BDGV0183.EUR","LU1066051225.USD","LU1914381329.SGD","LU1778281490.HKD","LU0889566641.SGD","BK4550","LU0795875169.SGD","BK4196","BK4588","LU1674673428.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0345770993.USD","IE000M9KFDE8.USD","SPRO","LU1057294990.SGD","LU0203345920.USD","LU0098860793.USD","IE00BSNM7G36.USD","LU1196500208.SGD","LU0058720904.USD","IE0009355771.USD","LU1261432733.SGD","JNJ","LU0122379950.USD","BK4581","LU1066051498.USD","CTMX","LU0466842654.USD","BK4139","IE00B4R5TH58.HKD","BK4585","BK4568"],"gpt_icon":0},{"id":"2494032546","title":"BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2494032546","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494032546?lang=en_us&edition=fundamental","pubTime":"2024-12-25 00:06","pubTimestamp":1735056360,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster immuno-oncology drug Opdivo  and Yervoy  for a new cancer indication.The EC has approved Opdivo plus Yervoy for the first-line treatment of adult patients with microsatellite instability–high  or mismatch repair deficient  unresectable or metastatic colorectal cancer .Following the latest nod, Opdivo plus Yervoy became the first dual checkpoint inhibitor therapy to be approved for the first-line treatment of MSI-H/dMMR mCRC in the European Union.The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Opdivo plus Yervoy for the given indication in November.Year to date, shares of Bristol Myers have rallied 12.2% against the industry’s decline of 13.7%.The latest approval for Opdivo plus Yervoy in first-line MSI-H/dMMR mCRC was based on data from the phase III CheckMate -8HW study.Also, the safety profile of Opdivo plus Yervoy","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tdykziZpl44jUPQqI7k0_g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8127f43af74d394c31adc7eb2e1fa286","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tdykziZpl44jUPQqI7k0_g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8127f43af74d394c31adc7eb2e1fa286"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmy-gets-ec-nod-opdivo-160600334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","LU1032466523.USD","LU1868837136.USD","LU1093756168.USD","SPRO","PFS","LU2242646821.SGD","LU0321505439.SGD","IE0002141913.USD","EC","LU1868837300.USD","BK4139","IE00B2B36J28.USD","BK4196","IE0009355771.USD","LU1093756325.SGD","BMY","LU1670711040.USD","LU1670711123.USD","BK4559","LU1585245621.USD","LU2133065610.SGD","IMCR","LU0321505868.SGD","BK4581","LU1571399168.USD","LU0225284248.USD","LU0114720955.EUR","BK4532","BK4588","BK4007","LU0868494617.USD","IE00BJT1NW94.SGD","CSTL","LU0096364046.USD","LU1670710588.SGD","LU1868836914.USD","BK4585","LU1989771016.USD","IE00BJJMRZ35.SGD","LU0456855351.SGD","IE00BFTCPJ56.SGD","LU1074936037.SGD","LU2125154935.USD","LU1261432733.SGD","LU0225771236.USD","BK4201","LU2242652126.USD","LU2360032135.SGD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2493797799","title":"Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek","url":"https://stock-news.laohu8.com/highlight/detail?id=2493797799","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493797799?lang=en_us&edition=fundamental","pubTime":"2024-12-24 02:44","pubTimestamp":1734979440,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis  aged six years and above. The drug will be marketed under the brand name Alyftrek.Post the FDA’s approval, the orally administered Alyftrek has been approved for use in CF patients aged six years and older who have at least one F508del mutation or another responsive mutation in the CF transmembrane conductance regulator  gene responsive to the drug. The drug will be available at a wholesale acquisition cost of $370,269 on an annual basis.The FDA’s decision came earlier than the expected PDUFA date of Jan 2, 2025. The approval is based on data from a comprehensive late-stage program, which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex’s blockbuster CF drug Trikafta , which is required to be administered twice daily. The drug is also eligible for use in CF patients who have discontinued Trikafta or Ve","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UgiI07ytew_hNcL7MgLFiA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UgiI07ytew_hNcL7MgLFiA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vertex-secures-fda-approval-cystic-184400620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","BK4567","LU0889565916.HKD","LU1069344957.HKD","IE00B19Z9P08.USD","IE00B2B36J28.USD","CSTL","LU0417517546.SGD","BK4093","BK4548","VTNR","LU0061475181.USD","IE00BFTCPJ56.SGD","BK4532","BK4023","LU1093756168.USD","VERX","BK4588","BK4534","BK4138","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4139","LU2362541513.USD","LU0256863811.USD","IE00BZ9MQY76.HKD","CTMX","BK4196","BK4501","LU1585245621.USD","IE0002141913.USD","LU2417539215.USD","LU0058720904.USD","LU0234570918.USD","VRTX","BK4533","BK4551","LU0109394709.USD","IE00B19Z3581.USD","LU2236285917.USD","LU1430594728.SGD","LU1093756325.SGD","CF","BK4585","MRNA","LU2237438978.USD","IE00B19Z3B42.SGD","LU2456880835.USD","LU2362541273.HKD","LU0079474960.USD"],"gpt_icon":0},{"id":"2493934307","title":"AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2493934307","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493934307?lang=en_us&edition=fundamental","pubTime":"2024-12-23 23:56","pubTimestamp":1734969360,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN announced that its blockbuster cancer drug, Tagrisso , has been approved in the EU for expanded use in non-small cell lung cancer .The eligible patient population includes adults with locally advanced, unresectable NSCLC with EGFR exon 19 deletions  or exon 21  substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy. The FDAapprovedthis combinationin September for a similar indication.The nod in the EU is based on data from the phase III LAURAstudy, which showed that treatment with Tagrisso reduced the risk of disease progression or death by 84% compared to placebo. Patients treated with the drug experienced a median progression-free survival of 39.1 months compared with 5.6 months for patients in the placebo group. The drugs’ safety and tolerability profiles were consistent with prior studies and no new safety concerns were identified.Last month, the EMA’s advisory committee adopted a positive opinion, recommendi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/spvq99_pwlnf7s60ZXBlKg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/06708d71c63051ca48bf1855727f077b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/spvq99_pwlnf7s60ZXBlKg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/06708d71c63051ca48bf1855727f077b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azns-tagrisso-gets-approval-eu-155600638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","BK4156","LU2236285917.USD","BK4196","LU0320765992.SGD","BK4139","LU2462157665.USD","BK4007","CTMX","LU1829250122.USD","LU2456880835.USD","LU2417539215.USD","SPRO","LU0109394709.USD","BK4585","BK4568","CSTL","BK4588","AZN"],"gpt_icon":0},{"id":"2493768415","title":"Analysts’ Top Healthcare Picks: Lifecore Biomedical (LFCR), Castle Biosciences (CSTL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2493768415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493768415?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:01","pubTimestamp":1734962472,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lifecore Biomedical (LFCR – Research Report) and Cas...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-lifecore-biomedical-lfcr-castle-biosciences-cstl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-lifecore-biomedical-lfcr-castle-biosciences-cstl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4212","CSTL","BK4137","BK4121","HCSG","LFCR"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":143,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSTL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-05","symbol":"CSTL","fiscalQuarterEnding":"2025/03","expectedEps":-0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746417600000,"reportTimeType":"post","actualEps":-0.2},{"market":"US","date":"2025-02-27","symbol":"CSTL","fiscalQuarterEnding":"2024/12","expectedEps":0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":0.32},{"market":"US","date":"2025-01-12","symbol":"CSTL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736658000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-04","symbol":"CSTL","fiscalQuarterEnding":"2024/09","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730696400000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2024-08-05","symbol":"CSTL","fiscalQuarterEnding":"2024/06","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSTL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5556,"buy":0.4444,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5556,"analysts":9,"updateTime":1702526400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSTL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSTL","date":"2025-06-18","current":-105.601247,"percent":0.189935,"low":-703.916349,"twenty":-97.974579,"median":-12.929442,"eighty":-4.870741,"high":155.734424,"avg":-50.760415,"sd":147.28801,"marketCap":535292720},"quantilePoints":[{"date":"2020-06-19","current":101.300632,"twenty":-137.181173,"median":72.096597,"eighty":89.912228,"marketCap":729871056},{"date":"2020-06-26","current":93.605957,"twenty":-130.766504,"median":72.216999,"eighty":90.734693,"marketCap":674430922},{"date":"2020-07-02","current":102.622433,"twenty":-129.220801,"median":72.241079,"eighty":91.444186,"marketCap":739394631},{"date":"2020-07-10","current":111.372149,"twenty":-123.084358,"median":72.843088,"eighty":91.857697,"marketCap":802436336},{"date":"2020-07-17","current":117.305694,"twenty":-115.1504,"median":73.469177,"eighty":92.281742,"marketCap":845187527},{"date":"2020-07-24","current":106.527432,"twenty":-106.40243,"median":74.167508,"eighty":92.916333,"marketCap":767530147},{"date":"2020-07-31","current":105.654256,"twenty":-102.767312,"median":74.396271,"eighty":93.757226,"marketCap":761238917},{"date":"2020-08-07","current":114.058572,"twenty":-101.783309,"median":74.456472,"eighty":94.202941,"marketCap":821792012},{"date":"2020-08-14","current":114.576879,"twenty":-98.400291,"median":74.981827,"eighty":94.738911,"marketCap":813266685},{"date":"2020-08-21","current":126.944083,"twenty":-97.554536,"median":75.780892,"eighty":96.467657,"marketCap":901049101},{"date":"2020-08-28","current":126.334042,"twenty":-95.952482,"median":76.635745,"eighty":97.420065,"marketCap":896719027},{"date":"2020-09-04","current":133.238602,"twenty":-93.309499,"median":76.98491,"eighty":99.303027,"marketCap":945727595},{"date":"2020-09-11","current":134.763705,"twenty":-92.601993,"median":77.514678,"eighty":100.272889,"marketCap":956552781},{"date":"2020-09-18","current":141.52962,"twenty":-91.068613,"median":78.020365,"eighty":102.449512,"marketCap":1004577242},{"date":"2020-09-25","current":137.592079,"twenty":-89.595469,"median":78.419535,"eighty":103.419182,"marketCap":976628580},{"date":"2020-10-02","current":142.611057,"twenty":-88.909949,"median":79.699487,"eighty":106.169125,"marketCap":1012253283},{"date":"2020-10-09","current":152.122158,"twenty":-87.950343,"median":80.235758,"eighty":108.912247,"marketCap":1079763078},{"date":"2020-10-16","current":138.5626,"twenty":-87.36482,"median":81.186932,"eighty":110.294181,"marketCap":983517335},{"date":"2020-10-23","current":143.747953,"twenty":-87.250969,"median":82.192491,"eighty":112.350606,"marketCap":1020322967},{"date":"2020-10-30","current":128.746478,"twenty":-87.169646,"median":82.764196,"eighty":114.265895,"marketCap":913842503},{"date":"2020-11-06","current":143.359744,"twenty":-86.063659,"median":84.023258,"eighty":116.079799,"marketCap":1017567465},{"date":"2020-11-13","current":-300.218351,"twenty":-87.950343,"median":82.764196,"eighty":115.530762,"marketCap":1002729291},{"date":"2020-11-20","current":-286.626257,"twenty":-92.601993,"median":82.192491,"eighty":115.132049,"marketCap":957331698},{"date":"2020-11-27","current":-265.105442,"twenty":-97.570801,"median":81.439776,"eighty":114.888032,"marketCap":885452175},{"date":"2020-12-04","current":-309.99512,"twenty":-109.964358,"median":80.259839,"eighty":114.369556,"marketCap":1035383700},{"date":"2020-12-11","current":-356.136701,"twenty":-134.615305,"median":79.885626,"eighty":113.96642,"marketCap":1189496581},{"date":"2020-12-18","current":-450.787075,"twenty":-141.029974,"median":78.954401,"eighty":113.756623,"marketCap":1505628832},{"date":"2020-12-24","current":-515.732815,"twenty":-143.704042,"median":78.164847,"eighty":113.491008,"marketCap":1722547602},{"date":"2020-12-31","current":-485.646593,"twenty":-146.146252,"median":77.835827,"eighty":112.857956,"marketCap":1622059619},{"date":"2021-01-08","current":-575.760614,"twenty":-151.556214,"median":77.346115,"eighty":112.012372,"marketCap":1923040451},{"date":"2021-01-15","current":-536.200125,"twenty":-153.642914,"median":76.720026,"eighty":111.384472,"marketCap":1790908417},{"date":"2021-01-22","current":-572.578418,"twenty":-155.265902,"median":76.491263,"eighty":111.374614,"marketCap":1912411915},{"date":"2021-01-29","current":-483.332268,"twenty":-167.600615,"median":75.585094,"eighty":110.83863,"marketCap":1614329774},{"date":"2021-02-05","current":-671.081866,"twenty":-169.640943,"median":74.685236,"eighty":110.157158,"marketCap":2241413434},{"date":"2021-02-12","current":-690.970595,"twenty":-171.341217,"median":74.456472,"eighty":109.561717,"marketCap":2307841788},{"date":"2021-02-19","current":-656.255723,"twenty":-173.845257,"median":74.33607,"eighty":109.348881,"marketCap":2191894116},{"date":"2021-02-26","current":-550.230719,"twenty":-178.868792,"median":74.167508,"eighty":109.144161,"marketCap":1837770601},{"date":"2021-03-05","current":-498.881637,"twenty":-200.184042,"median":73.01165,"eighty":108.912247,"marketCap":1666264669},{"date":"2021-03-12","current":-155.908697,"twenty":-197.741831,"median":72.590244,"eighty":108.442961,"marketCap":1603365036},{"date":"2021-03-19","current":-161.592235,"twenty":-187.710216,"median":72.241079,"eighty":107.618901,"marketCap":1661814548},{"date":"2021-03-26","current":-145.658896,"twenty":-181.094605,"median":72.144757,"eighty":106.811214,"marketCap":1497956087},{"date":"2021-04-01","current":-172.643561,"twenty":-179.425246,"median":72.072517,"eighty":106.28856,"marketCap":1775466377},{"date":"2021-04-09","current":-168.830246,"twenty":-179.507526,"median":71.807633,"eighty":105.852599,"marketCap":1736250252},{"date":"2021-04-16","current":-159.114795,"twenty":-178.054894,"median":70.96482,"eighty":105.703373,"marketCap":1636336556},{"date":"2021-04-23","current":-164.142541,"twenty":-177.570402,"median":70.844418,"eighty":105.135102,"marketCap":1688041893},{"date":"2021-04-30","current":-168.180083,"twenty":-176.766636,"median":70.627694,"eighty":103.731578,"marketCap":1729563976},{"date":"2021-05-07","current":-146.959621,"twenty":-175.143647,"median":69.495918,"eighty":102.75377,"marketCap":1511332740},{"date":"2021-05-14","current":-91.341496,"twenty":-173.860714,"median":69.134713,"eighty":102.6761,"marketCap":1382362194},{"date":"2021-05-21","current":-95.480588,"twenty":-173.49996,"median":68.484543,"eighty":102.639567,"marketCap":1445003222},{"date":"2021-05-28","current":-99.222328,"twenty":-172.874456,"median":67.172163,"eighty":102.507152,"marketCap":1501630711},{"date":"2021-06-04","current":-104.801825,"twenty":-172.506749,"median":65.944065,"eighty":102.127511,"marketCap":1586070816},{"date":"2021-06-11","current":-119.023747,"twenty":-171.940864,"median":65.462458,"eighty":101.207424,"marketCap":1801305386},{"date":"2021-06-18","current":-121.623097,"twenty":-171.761303,"median":65.089212,"eighty":100.776014,"marketCap":1840643952},{"date":"2021-06-25","current":-121.490646,"twenty":-171.341217,"median":64.848409,"eighty":100.452102,"marketCap":1838639439},{"date":"2021-07-02","current":-117.450892,"twenty":-171.339369,"median":64.547404,"eighty":99.99422,"marketCap":1777501796},{"date":"2021-07-09","current":-121.507203,"twenty":-171.331975,"median":62.921979,"eighty":99.596394,"marketCap":1838890003},{"date":"2021-07-16","current":-107.599851,"twenty":-170.645651,"median":-30.05226,"eighty":99.432751,"marketCap":1628416150},{"date":"2021-07-23","current":-113.907828,"twenty":-170.627605,"median":-66.775802,"eighty":99.270596,"marketCap":1723881076},{"date":"2021-07-30","current":-115.646247,"twenty":-170.259225,"median":-79.533458,"eighty":98.781094,"marketCap":1750190308},{"date":"2021-08-06","current":-118.907852,"twenty":-170.259225,"median":-80.976934,"eighty":98.358362,"marketCap":1799551438},{"date":"2021-08-13","current":-71.922702,"twenty":-169.486373,"median":-79.89941,"eighty":97.576447,"marketCap":1621785000},{"date":"2021-08-20","current":-73.898232,"twenty":-168.830246,"median":-78.110313,"eighty":97.380969,"marketCap":1666331236},{"date":"2021-08-27","current":-82.916473,"twenty":-168.790806,"median":-79.533458,"eighty":97.12033,"marketCap":1869683545},{"date":"2021-09-03","current":-85.70677,"twenty":-168.558951,"median":-80.554542,"eighty":96.729373,"marketCap":1932601958},{"date":"2021-09-10","current":-83.128535,"twenty":-168.255857,"median":-81.000595,"eighty":96.620807,"marketCap":1874465345},{"date":"2021-09-17","current":-86.298313,"twenty":-167.864896,"median":-81.677581,"eighty":96.467657,"marketCap":1945940661},{"date":"2021-09-24","current":-80.851653,"twenty":-167.600615,"median":-81.817096,"eighty":96.094956,"marketCap":1823123920},{"date":"2021-10-01","current":-72.927209,"twenty":-167.548158,"median":-81.052554,"eighty":95.725323,"marketCap":1644435629},{"date":"2021-10-08","current":-68.418088,"twenty":-166.747019,"median":-80.939604,"eighty":95.341474,"marketCap":1542759474},{"date":"2021-10-15","current":-70.962839,"twenty":-166.488822,"median":-80.193143,"eighty":94.738911,"marketCap":1600141066},{"date":"2021-10-22","current":-70.014138,"twenty":-166.318802,"median":-79.455917,"eighty":94.477414,"marketCap":1578748806},{"date":"2021-10-29","current":-69.590013,"twenty":-165.92895,"median":-79.054701,"eighty":94.395866,"marketCap":1569185207},{"date":"2021-11-05","current":-66.46488,"twenty":-165.628697,"median":-75.845859,"eighty":94.279373,"marketCap":1498716585},{"date":"2021-11-12","current":-43.948833,"twenty":-165.400692,"median":-74.221907,"eighty":94.202941,"marketCap":1307521726},{"date":"2021-11-19","current":-40.394148,"twenty":-165.136289,"median":-73.228561,"eighty":94.032207,"marketCap":1201766292},{"date":"2021-11-26","current":-36.669382,"twenty":-164.802892,"median":-72.66492,"eighty":93.911867,"marketCap":1090950790},{"date":"2021-12-03","current":-35.232201,"twenty":-164.332488,"median":-72.525406,"eighty":93.857997,"marketCap":1048193210},{"date":"2021-12-10","current":-35.043363,"twenty":-164.069675,"median":-71.699478,"eighty":93.782419,"marketCap":1042575102},{"date":"2021-12-17","current":-36.565484,"twenty":-163.125113,"median":-70.962839,"eighty":93.656387,"marketCap":1087859706},{"date":"2021-12-23","current":-36.824936,"twenty":-162.260438,"median":-70.538714,"eighty":93.390391,"marketCap":1095578673},{"date":"2021-12-31","current":-37.07574,"twenty":-161.75254,"median":-70.326651,"eighty":93.033305,"marketCap":1103040341},{"date":"2022-01-07","current":-33.80664,"twenty":-160.853861,"median":-70.081106,"eighty":92.949516,"marketCap":1005781361},{"date":"2022-01-14","current":-31.297701,"twenty":-159.513129,"median":-69.768592,"eighty":92.804142,"marketCap":931137898},{"date":"2022-01-21","current":-28.661836,"twenty":-159.163373,"median":-69.221694,"eighty":92.613304,"marketCap":852718272},{"date":"2022-01-28","current":-32.764914,"twenty":-159.153657,"median":-68.462733,"eighty":92.417037,"marketCap":974788953},{"date":"2022-02-04","current":-36.620613,"twenty":-159.037071,"median":-68.077672,"eighty":92.363653,"marketCap":1089499863},{"date":"2022-02-11","current":-37.07272,"twenty":-158.52701,"median":-67.458226,"eighty":92.230539,"marketCap":1102950479},{"date":"2022-02-18","current":-33.933566,"twenty":-157.725045,"median":-66.676942,"eighty":92.12856,"marketCap":1009557525},{"date":"2022-02-25","current":-38.121947,"twenty":-157.70385,"median":-56.620469,"eighty":92.103044,"marketCap":1134166058},{"date":"2022-03-04","current":-34.317143,"twenty":-156.502465,"median":-46.976268,"eighty":91.895938,"marketCap":1073852040},{"date":"2022-03-11","current":-32.441312,"twenty":-155.908697,"median":-44.969316,"eighty":91.848137,"marketCap":1015153549},{"date":"2022-03-18","current":-36.6396,"twenty":-155.213239,"median":-44.561123,"eighty":91.680837,"marketCap":1146526362},{"date":"2022-03-25","current":-34.406468,"twenty":-154.956761,"median":-41.163763,"eighty":91.549188,"marketCap":1076647206},{"date":"2022-04-01","current":-37.337961,"twenty":-153.952054,"median":-39.575131,"eighty":91.549188,"marketCap":1168379479},{"date":"2022-04-08","current":-26.594568,"twenty":-153.917029,"median":-38.48489,"eighty":91.417935,"marketCap":832197215},{"date":"2022-04-14","current":-21.064522,"twenty":-153.883221,"median":-38.135515,"eighty":91.392618,"marketCap":659151015},{"date":"2022-04-22","current":-18.65924,"twenty":-153.705343,"median":-38.019584,"eighty":91.277765,"marketCap":583884947},{"date":"2022-04-29","current":-18.194999,"twenty":-153.646928,"median":-37.870138,"eighty":90.837881,"marketCap":569357910},{"date":"2022-05-06","current":-17.742098,"twenty":-153.581085,"median":-37.62719,"eighty":90.669444,"marketCap":555185744},{"date":"2022-05-13","current":-10.02426,"twenty":-153.127806,"median":-37.342022,"eighty":90.431678,"marketCap":517602654},{"date":"2022-05-20","current":-11.01092,"twenty":-152.745149,"median":-37.268917,"eighty":90.138886,"marketCap":568548831},{"date":"2022-05-27","current":-11.534765,"twenty":-152.15131,"median":-37.07423,"eighty":89.945688,"marketCap":595597574},{"date":"2022-06-03","current":-9.714021,"twenty":-151.992333,"median":-36.988631,"eighty":89.740147,"marketCap":501583495},{"date":"2022-06-10","current":-9.890877,"twenty":-151.80124,"median":-36.824936,"eighty":89.553726,"marketCap":510715451},{"date":"2022-06-17","current":-8.14483,"twenty":-151.608171,"median":-36.696416,"eighty":89.491586,"marketCap":420558272},{"date":"2022-06-24","current":-12.130705,"twenty":-151.344402,"median":-36.658551,"eighty":89.461816,"marketCap":626368976},{"date":"2022-07-01","current":-11.458757,"twenty":-150.793512,"median":-36.620613,"eighty":89.366342,"marketCap":591672918},{"date":"2022-07-08","current":-13.133538,"twenty":-150.278593,"median":-36.428467,"eighty":89.249147,"marketCap":678150213},{"date":"2022-07-15","current":-12.588852,"twenty":-149.603714,"median":-36.089951,"eighty":89.1582,"marketCap":650025379},{"date":"2022-07-22","current":-12.950279,"twenty":-149.104402,"median":-35.730106,"eighty":89.071615,"marketCap":668687652},{"date":"2022-07-29","current":-14.23309,"twenty":-147.282584,"median":-35.640177,"eighty":88.843853,"marketCap":734925580},{"date":"2022-08-05","current":-15.556624,"twenty":-147.050863,"median":-35.579565,"eighty":88.468661,"marketCap":803266299},{"date":"2022-08-12","current":-20.060215,"twenty":-146.936061,"median":-35.460837,"eighty":88.420861,"marketCap":892519093},{"date":"2022-08-19","current":-18.842653,"twenty":-146.702706,"median":-35.366658,"eighty":88.334821,"marketCap":838347339},{"date":"2022-08-26","current":-18.287067,"twenty":-146.099345,"median":-35.166981,"eighty":87.890279,"marketCap":813628189},{"date":"2022-09-02","current":-16.543472,"twenty":-145.861154,"median":-35.147161,"eighty":86.833894,"marketCap":736052134},{"date":"2022-09-09","current":-17.335478,"twenty":-145.658896,"median":-35.015504,"eighty":86.661813,"marketCap":771290071},{"date":"2022-09-16","current":-16.04699,"twenty":-144.832405,"median":-34.913637,"eighty":86.238683,"marketCap":713962681},{"date":"2022-09-23","current":-14.569367,"twenty":-144.059553,"median":-34.541755,"eighty":85.557518,"marketCap":648220261},{"date":"2022-09-30","current":-15.414567,"twenty":-143.904983,"median":-34.361806,"eighty":85.203906,"marketCap":685824925},{"date":"2022-10-07","current":-15.733734,"twenty":-143.10859,"median":-34.256358,"eighty":84.606403,"marketCap":700025288},{"date":"2022-10-14","current":-13.014907,"twenty":-142.900276,"median":-33.942644,"eighty":84.37758,"marketCap":579059235},{"date":"2022-10-21","current":-12.701651,"twenty":-142.591135,"median":-33.780695,"eighty":84.023258,"marketCap":565121842},{"date":"2022-10-28","current":-13.848286,"twenty":-141.740998,"median":-33.572754,"eighty":83.567141,"marketCap":616137960},{"date":"2022-11-04","current":-10.918859,"twenty":-139.963439,"median":-33.417462,"eighty":82.764196,"marketCap":578153577},{"date":"2022-11-11","current":-11.152763,"twenty":-139.808869,"median":-32.603113,"eighty":82.764196,"marketCap":590538818},{"date":"2022-11-18","current":-10.45105,"twenty":-139.422443,"median":-31.297701,"eighty":82.306669,"marketCap":553383096},{"date":"2022-11-25","current":-10.585421,"twenty":-137.629427,"median":-30.939428,"eighty":82.215327,"marketCap":560498021},{"date":"2022-12-02","current":-12.795071,"twenty":-137.051739,"median":-30.146712,"eighty":81.917812,"marketCap":677499018},{"date":"2022-12-09","current":-11.107973,"twenty":-132.017079,"median":-29.830488,"eighty":81.521649,"marketCap":588167176},{"date":"2022-12-16","current":-11.978894,"twenty":-129.220801,"median":-29.148408,"eighty":81.035226,"marketCap":634282434},{"date":"2022-12-23","current":-11.560852,"twenty":-127.462725,"median":-28.661836,"eighty":80.413953,"marketCap":612147110},{"date":"2022-12-30","current":-11.715129,"twenty":-126.444312,"median":-28.295032,"eighty":80.255022,"marketCap":620316099},{"date":"2023-01-06","current":-11.346854,"twenty":-125.431062,"median":-25.10852,"eighty":80.129804,"marketCap":600815932},{"date":"2023-01-13","current":-13.541575,"twenty":-124.480726,"median":-21.758823,"eighty":79.936775,"marketCap":717026382},{"date":"2023-01-20","current":-13.257903,"twenty":-124.252248,"median":-20.468425,"eighty":79.81117,"marketCap":702005984},{"date":"2023-01-27","current":-12.939395,"twenty":-123.914499,"median":-20.219799,"eighty":79.508532,"marketCap":685140976},{"date":"2023-02-03","current":-14.084034,"twenty":-123.669464,"median":-19.981754,"eighty":79.275321,"marketCap":745749600},{"date":"2023-02-10","current":-13.1733,"twenty":-123.391317,"median":-19.773366,"eighty":78.392678,"marketCap":697526216},{"date":"2023-02-17","current":-12.939395,"twenty":-122.237123,"median":-19.352035,"eighty":78.237088,"marketCap":685140976},{"date":"2023-02-24","current":-12.123218,"twenty":-121.646854,"median":-19.194328,"eighty":78.044446,"marketCap":641924391},{"date":"2023-03-03","current":-9.769225,"twenty":-121.623097,"median":-18.990416,"eighty":77.996285,"marketCap":655886202},{"date":"2023-03-10","current":-7.706921,"twenty":-121.507203,"median":-18.763163,"eighty":77.67537,"marketCap":517427243},{"date":"2023-03-17","current":-8.470884,"twenty":-121.490646,"median":-18.651096,"eighty":77.514678,"marketCap":568718182},{"date":"2023-03-24","current":-8.910261,"twenty":-121.407864,"median":-18.327158,"eighty":77.346115,"marketCap":598217116},{"date":"2023-03-31","current":-8.993387,"twenty":-120.530377,"median":-18.243867,"eighty":76.98491,"marketCap":603797995},{"date":"2023-04-06","current":-8.827136,"twenty":-120.25223,"median":-18.109752,"eighty":76.792267,"marketCap":592636236},{"date":"2023-04-14","current":-9.233586,"twenty":-119.573419,"median":-17.654644,"eighty":76.705578,"marketCap":619924514},{"date":"2023-04-21","current":-9.5476,"twenty":-119.262158,"median":-17.35912,"eighty":76.599624,"marketCap":641006751},{"date":"2023-04-28","current":-8.804302,"twenty":-119.063482,"median":-17.187715,"eighty":76.440694,"marketCap":591103228},{"date":"2023-05-05","current":-8.18984,"twenty":-118.984012,"median":-16.797623,"eighty":75.90611,"marketCap":587367135},{"date":"2023-05-12","current":-8.442866,"twenty":-118.921097,"median":-16.759205,"eighty":75.624254,"marketCap":605513871},{"date":"2023-05-19","current":-8.747984,"twenty":-118.854872,"median":-16.543472,"eighty":75.272328,"marketCap":627396699},{"date":"2023-05-26","current":-9.369385,"twenty":-118.099901,"median":-16.162244,"eighty":74.854441,"marketCap":671962947},{"date":"2023-06-02","current":-7.832628,"twenty":-117.894602,"median":-15.796084,"eighty":74.668379,"marketCap":561748214},{"date":"2023-06-09","current":-5.33214,"twenty":-117.642945,"median":-15.68645,"eighty":74.514265,"marketCap":382415768},{"date":"2023-06-16","current":-4.986091,"twenty":-117.464137,"median":-15.580163,"eighty":74.456472,"marketCap":357597438},{"date":"2023-06-23","current":-4.930276,"twenty":-117.424402,"median":-15.417523,"eighty":74.456472,"marketCap":353594482},{"date":"2023-06-30","current":-4.933997,"twenty":-117.219102,"median":-15.257939,"eighty":74.432392,"marketCap":353861345},{"date":"2023-07-07","current":-4.941439,"twenty":-116.556848,"median":-15.108846,"eighty":74.33607,"marketCap":354395073},{"date":"2023-07-14","current":-6.02796,"twenty":-116.507179,"median":-14.859223,"eighty":74.263829,"marketCap":432319291},{"date":"2023-07-21","current":-6.214009,"twenty":-115.646247,"median":-14.557546,"eighty":74.167508,"marketCap":445662479},{"date":"2023-07-28","current":-5.894006,"twenty":-115.613135,"median":-14.258542,"eighty":74.167508,"marketCap":422712195},{"date":"2023-08-04","current":-5.663815,"twenty":-115.513796,"median":-14.240825,"eighty":73.926704,"marketCap":503218594},{"date":"2023-08-11","current":-5.280594,"twenty":-114.553527,"median":-14.178591,"eighty":73.01165,"marketCap":469170240},{"date":"2023-08-18","current":-5.208175,"twenty":-113.907828,"median":-14.052198,"eighty":72.867168,"marketCap":462735905},{"date":"2023-08-25","current":-5.64571,"twenty":-113.791934,"median":-13.89557,"eighty":72.843088,"marketCap":501610010},{"date":"2023-09-01","current":-6.013843,"twenty":-113.659483,"median":-13.834522,"eighty":72.3374,"marketCap":534317879},{"date":"2023-09-08","current":-5.66985,"twenty":-113.552925,"median":-13.793063,"eighty":72.260343,"marketCap":503754789},{"date":"2023-09-15","current":-5.310769,"twenty":-113.447412,"median":-13.581503,"eighty":72.241079,"marketCap":471851212},{"date":"2023-09-22","current":-5.027126,"twenty":-113.123056,"median":-13.47439,"eighty":72.241079,"marketCap":446650068},{"date":"2023-09-29","current":-5.247402,"twenty":-111.576691,"median":-13.437064,"eighty":72.20255,"marketCap":466221169},{"date":"2023-10-06","current":-4.483979,"twenty":-111.103179,"median":-13.330065,"eighty":72.115861,"marketCap":398392558},{"date":"2023-10-13","current":-3.678311,"twenty":-110.692581,"median":-13.257903,"eighty":72.096597,"marketCap":326810584},{"date":"2023-10-20","current":-3.862378,"twenty":-109.828339,"median":-13.190718,"eighty":72.058068,"marketCap":343164518},{"date":"2023-10-27","current":-3.946867,"twenty":-109.228998,"median":-13.161054,"eighty":72.033988,"marketCap":350671242},{"date":"2023-11-03","current":-5.912031,"twenty":-107.583295,"median":-13.139027,"eighty":71.942483,"marketCap":446381971},{"date":"2023-11-10","current":-6.105341,"twenty":-107.470712,"median":-13.073766,"eighty":71.720944,"marketCap":460977687},{"date":"2023-11-17","current":-6.860935,"twenty":-106.821702,"median":-13.014907,"eighty":71.306761,"marketCap":518028049},{"date":"2023-11-24","current":-7.085475,"twenty":-104.967388,"median":-12.997175,"eighty":71.037061,"marketCap":534981694},{"date":"2023-12-01","current":-7.12468,"twenty":-104.801825,"median":-12.950279,"eighty":70.892579,"marketCap":537941854},{"date":"2023-12-08","current":-6.878756,"twenty":-104.621466,"median":-12.939395,"eighty":70.868499,"marketCap":519373576},{"date":"2023-12-15","current":-7.345656,"twenty":-102.303773,"median":-12.93329,"eighty":70.844418,"marketCap":554626394},{"date":"2023-12-22","current":-7.766222,"twenty":-101.653193,"median":-12.899374,"eighty":70.675856,"marketCap":586380840},{"date":"2023-12-29","current":-7.994326,"twenty":-101.138387,"median":-12.831107,"eighty":70.661407,"marketCap":603603591},{"date":"2024-01-05","current":-7.242296,"twenty":-100.480612,"median":-12.765211,"eighty":70.642143,"marketCap":546822335},{"date":"2024-01-12","current":-7.345656,"twenty":-99.17597,"median":-12.686153,"eighty":70.492844,"marketCap":554626394},{"date":"2024-01-19","current":-6.957166,"twenty":-98.990539,"median":-12.535401,"eighty":70.049766,"marketCap":525293896},{"date":"2024-01-26","current":-7.356348,"twenty":-98.377953,"median":-12.367076,"eighty":69.495918,"marketCap":555433710},{"date":"2024-02-02","current":-8.439841,"twenty":-98.245502,"median":-12.314821,"eighty":69.375516,"marketCap":637241776},{"date":"2024-02-09","current":-8.500431,"twenty":-97.897818,"median":-12.148101,"eighty":69.255114,"marketCap":641816569},{"date":"2024-02-16","current":-8.867536,"twenty":-97.587065,"median":-12.126962,"eighty":69.014311,"marketCap":669534434},{"date":"2024-02-23","current":-8.682202,"twenty":-97.554536,"median":-12.050186,"eighty":68.879461,"marketCap":655540949},{"date":"2024-03-01","current":-8.626783,"twenty":-97.496408,"median":-11.968941,"eighty":68.556784,"marketCap":495746692},{"date":"2024-03-08","current":-9.911724,"twenty":-97.444174,"median":-11.921994,"eighty":68.446014,"marketCap":569587147},{"date":"2024-03-15","current":-9.219098,"twenty":-97.381259,"median":-11.8495,"eighty":67.954775,"marketCap":529784671},{"date":"2024-03-22","current":-10.07891,"twenty":-97.328279,"median":-11.779827,"eighty":66.774837,"marketCap":579194641},{"date":"2024-03-28","current":-10.164891,"twenty":-96.980595,"median":-11.747478,"eighty":66.394368,"marketCap":584135638},{"date":"2024-04-05","current":-10.145784,"twenty":-96.034573,"median":-11.715129,"eighty":65.869416,"marketCap":583037638},{"date":"2024-04-12","current":-9.975623,"twenty":-95.509954,"median":-11.674233,"eighty":65.541923,"marketCap":573259148},{"date":"2024-04-19","current":-9.21713,"twenty":-93.841259,"median":-11.590712,"eighty":65.486538,"marketCap":529671590},{"date":"2024-04-26","current":-9.365948,"twenty":-92.601993,"median":-11.540343,"eighty":65.296304,"marketCap":538223579},{"date":"2024-05-03","current":-20.460076,"twenty":-92.472226,"median":-11.516062,"eighty":65.156637,"marketCap":630088496},{"date":"2024-05-10","current":-21.891395,"twenty":-91.785206,"median":-11.553387,"eighty":65.07958,"marketCap":674167408},{"date":"2024-05-17","current":-21.712105,"twenty":-90.954077,"median":-11.630526,"eighty":64.939914,"marketCap":668645972},{"date":"2024-05-24","current":-21.281807,"twenty":-90.477253,"median":-11.705647,"eighty":64.858041,"marketCap":655394524},{"date":"2024-05-31","current":-21.70314,"twenty":-90.243501,"median":-11.725082,"eighty":64.752087,"marketCap":668369900},{"date":"2024-06-07","current":-20.645325,"twenty":-89.767451,"median":-11.754943,"eighty":64.597973,"marketCap":635793424},{"date":"2024-06-14","current":-20.331566,"twenty":-89.137652,"median":-11.784803,"eighty":64.569077,"marketCap":626130910},{"date":"2024-06-21","current":-18.888276,"twenty":-88.682246,"median":-11.8495,"eighty":64.511283,"marketCap":581683345},{"date":"2024-06-28","current":-18.968957,"twenty":-88.19431,"median":-11.87936,"eighty":63.91409,"marketCap":584167992},{"date":"2024-07-05","current":-19.049638,"twenty":-87.429878,"median":-11.962718,"eighty":62.979772,"marketCap":586652638},{"date":"2024-07-12","current":-16.575426,"twenty":-87.283498,"median":-11.973917,"eighty":62.661912,"marketCap":510456813},{"date":"2024-07-15","current":-16.629213,"twenty":-87.267233,"median":-11.978894,"eighty":62.498165,"marketCap":512113244},{"date":"2024-08-02","current":-20.654289,"twenty":-86.610826,"median":-11.921994,"eighty":63.018301,"marketCap":636069496},{"date":"2024-08-09","current":-249.174378,"twenty":-87.299762,"median":-11.921994,"eighty":63.018301,"marketCap":772191398},{"date":"2024-08-16","current":-242.909218,"twenty":-92.450772,"median":-11.921994,"eighty":63.018301,"marketCap":752775666},{"date":"2024-08-23","current":-246.399807,"twenty":-97.318345,"median":-11.921994,"eighty":63.018301,"marketCap":763593002},{"date":"2024-08-30","current":-266.627325,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":826278080},{"date":"2024-09-06","current":-263.852754,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":817679684},{"date":"2024-09-13","current":-274.593029,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":850963796},{"date":"2024-09-20","current":-273.250494,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":846803282},{"date":"2024-09-27","current":-250.606415,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":776629280},{"date":"2024-10-04","current":-254.365511,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":788278719},{"date":"2024-10-11","current":-253.291484,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":784950308},{"date":"2024-10-18","current":-295.894574,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":916977285},{"date":"2024-10-25","current":-284.617286,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":882028968},{"date":"2024-10-31","current":-309.140913,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":958027690},{"date":"2024-11-08","current":153.567604,"twenty":-91.563351,"median":-11.784803,"eighty":64.853225,"marketCap":932923196},{"date":"2024-11-15","current":142.134171,"twenty":-90.404405,"median":-11.754943,"eighty":65.240919,"marketCap":863465089},{"date":"2024-11-22","current":133.144173,"twenty":-90.404405,"median":-11.754943,"eighty":65.474498,"marketCap":808850852},{"date":"2024-11-29","current":139.598531,"twenty":-90.404405,"median":-11.754943,"eighty":66.977112,"marketCap":848061074},{"date":"2024-12-06","current":148.265811,"twenty":-90.404405,"median":-11.754943,"eighty":69.332172,"marketCap":900714800},{"date":"2024-12-13","current":134.250635,"twenty":-90.404405,"median":-11.754943,"eighty":70.85405,"marketCap":815572605},{"date":"2024-12-20","current":124.891816,"twenty":-90.404405,"median":-11.754943,"eighty":71.990643,"marketCap":758717784},{"date":"2024-12-27","current":124.937919,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":758997857},{"date":"2025-01-03","current":129.271559,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":785324720},{"date":"2025-01-10","current":150.847554,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":916398888},{"date":"2025-01-17","current":115.671306,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":702703182},{"date":"2025-01-24","current":122.171766,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":742193476},{"date":"2025-01-31","current":130.101405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":790366034},{"date":"2025-02-07","current":128.303405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":779443186},{"date":"2025-02-14","current":127.289149,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":773281580},{"date":"2025-02-21","current":120.558176,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":732390921},{"date":"2025-02-28","current":38.806499,"twenty":-90.477253,"median":-11.764897,"eighty":76.356928,"marketCap":708024569},{"date":"2025-03-07","current":32.178981,"twenty":-90.550101,"median":-11.77485,"eighty":73.454249,"marketCap":587105504},{"date":"2025-03-14","current":29.318974,"twenty":-90.550101,"median":-11.77485,"eighty":33.288601,"marketCap":534924684},{"date":"2025-03-21","current":31.366301,"twenty":-90.550101,"median":-11.77485,"eighty":31.49758,"marketCap":572278167},{"date":"2025-03-28","current":31.413187,"twenty":-90.550101,"median":-11.77485,"eighty":31.375678,"marketCap":573133590},{"date":"2025-04-04","current":29.990998,"twenty":-90.550101,"median":-11.77485,"eighty":31.063109,"marketCap":547185751},{"date":"2025-04-11","current":30.162911,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":550322303},{"date":"2025-04-17","current":33.226087,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":606209957},{"date":"2025-04-25","current":33.089862,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":603724531},{"date":"2025-05-02","current":30.528678,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":556995733},{"date":"2025-05-09","current":-98.025753,"twenty":-95.154431,"median":-11.87936,"eighty":29.478384,"marketCap":496892541},{"date":"2025-05-16","current":-93.867775,"twenty":-96.90247,"median":-11.978894,"eighty":-3.786337,"marketCap":475815751},{"date":"2025-05-23","current":-90.507217,"twenty":-96.90247,"median":-12.148101,"eighty":-3.979456,"marketCap":458781085},{"date":"2025-05-30","current":-90.848969,"twenty":-96.90247,"median":-12.322286,"eighty":-4.309569,"marketCap":460513424},{"date":"2025-06-06","current":-96.943539,"twenty":-96.977714,"median":-12.588852,"eighty":-4.550363,"marketCap":491406801},{"date":"2025-06-13","current":-107.196088,"twenty":-97.40775,"median":-12.795071,"eighty":-4.74909,"marketCap":543376968},{"date":"2025-06-18","current":-105.601247,"twenty":-97.974579,"median":-12.929442,"eighty":-4.870741,"marketCap":535292720}],"updateTime":1750335427748}}}